title: Seroreversion in vertically HIV-1-infected children treated early and efficiently: rule or exception?
authors.forename: Josef
authors.initials: J
authors.lastname: Eberle
authors.forename: Gundula
authors.initials: G
authors.lastname: Notheis
authors.forename: Claudia
authors.initials: C
authors.lastname: Blattmann
authors.forename: Jutta
authors.initials: J
authors.lastname: Jung
authors.forename: Bernd
authors.initials: B
authors.lastname: Buchholz
authors.forename: Klaus
authors.initials: K
authors.lastname: Korn
authors.forename: Andreas E
authors.initials: AE
authors.lastname: Kulozik
authors.forename: Paul
authors.initials: P
authors.lastname: Schnitzler
mesh_terms: D019380:Anti-HIV Agents / Q000627:therapeutic use*; D002648:Child; D002675:Child, Preschool; D004334:Drug Administration Schedule; D005260:Female; D015483:HIV Antibodies / Q000097:blood*; D015658:HIV Infections / Q000188:drug therapy*; D015497:HIV-1; D006801:Humans; D007223:Infant; D008297:Male; D012367:RNA, Viral; D019562:Viral Load
chemical_list: D019380:Anti-HIV Agents; D015483:HIV Antibodies; D012367:RNA, Viral